The DOI matches its Crossref record; 55 of the 59 references it cites were found in a registry or an index.
p53 is frequently mutated in Burkitt's lymphoma cell lines
Open accessAbstract
A panel of 12 Burkitt's lymphoma cell lines and four other B cell lines were tested for the presence of mutations in p53. Protein analysis using a mutant-specific antibody and sequencing of both cDNA and genomic DNA revealed changes relative to the standard p53 protein sequence in 12 of the 16 lines studied, including 10 of the BL lines. Mutation of p53 in the BL lines was usually accompanied by loss of the other allele of p53. Testing of the mutated p53 cDNAs for gain of transforming activity or loss of growth suppression activity showed that several of the BL mutants were functionally altered from wild-type p53.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The cell line RAJI, which harbors the loss-of-function mutant alleles R213Q and Y234H [34–36] for p53 targets including TLR3 and p21 (Supplementary Figure S4A), was treated with the reactivating drugs RITA [36] and PRIMA-1 [37] as well as with the anticancer drugs doxorubicin (DXR) and 5-fluorouracil (5FU) to induce p53.”
From Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells (2016) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
Feinberg, A. P., & Vogelstein, B. (1983) · Analytical Biochemistry · doi:10.1016/0003-2697(83)90418-9 · Cited by 24,512
Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.
Thomas, P. S. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.9.5201 · Cited by 7,937
Aviv, H., & Leder, P. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.6.1408 · Cited by 6,636
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K. R., Signer, S. H., Davidson, N. E., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,730
McMaster, G. K., & Carmichael, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.11.4835 · Cited by 2,406
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Dalla‐Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C., & Croce, C. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7824 · Cited by 1,764
Research works printed but not linked: 13
- Aviv,H. and Leder,P. (1972) Proc. Nat!. Acad. Sci. USA, 64, 1408-1412.
- Dalla-Favera,R., Brejni,M., Erikson,J., Patterson,D., Gallo, R.C. and Croce,C.M. (1982) Proc. Natl. Acad. Sci. USA, 79, 7824-7827.
- Eliyahu,D., Michalovitz,D., Eliyahu,S., Pinhasi-Kimhi,O. and Oren,M. (1989) Proc. Natl. Acad. Sci. USA, 86, 8763-8767.
- Hinuma,Y. and Grace,J.T. (1967) Proc. Soc. Exp. Biol. Med., 124, 107-111.
- Hollstein,M.C., Metcalf,R.A., Welsh,J.A., Montesano,R. and Harris,C.C. (1990) Proc. Natl. Acad. Sci. USA, 87, 9958-9961.
- Lenoir,G.M., Vuillaume,M. and Bonnardel,C. (1985) IARC Publications No 60, pp. 309-318.
- McMaster,G.K. and Carmichael,G.C. (1977) Proc. Natl. Acad. Sci. USA, 74, 4835-4838.
- Miller,G., Shope,T., Lisco,H., Stitt,D. and Lipman,M. (1972) Proc. Natl. Acad. Sci. USA, 69, 383-387
- Rodrigues,N.R., Rowan,A., Smith,M.E.G., Kerr,I.B., Bodmer,W.F., Gannon,J.F. and Lane,D.P. (1990) Proc. Natl. Acad. Sci. USA, 87, 7555 -7559.
- Sanger,F., Nicklen,S. and Coulson,A.R. (1977) Proc. Natl. Acad. Sci. USA, 74, 5463-5467.
- Thomas,P.S. (1980) Proc. Natl. Acad. Sci. USA, 77, 5201-5205.
- van Santen,V., Cheung,A. and Kieff,E. (1981) Proc. Natl. Acad. Sci. USA, 78, 1930-1934
- zur Hausen,H., Schulte-Holthausen,H., Klein,G., Henle,W., Henle,G., Clifford,P. and Santesson,L. (1970) Nature, 228, 1056-1058. Received on April 30, 1991; revised on June 5, 1991 Note added in proof Mutations of p53 in BL have also been reported recently by Gaidano et al. (1991) (Proc. Natl. Acad. Sci. USA, 88. 5413-5417).
Cited by
Sorted by citations
Items 201–254 of 254
p53 Protein Expression in Leukemias
Paydaş, S. (1995) · Acta Oncologica · doi:10.3109/02841869509093633 · Cited by 6
Ötvös, L., Hoffmann, R., Xiang, Z., O‐Sullivan, I., Deng, H., Wysocka, M., Pease, A. M., Rogers, M. E., Blaszczyk‐Thurin, M., & Ertl, H. C. J. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(98)00087-1 · Cited by 6
The master antioxidant defense is activated during EBV latent infection
Wang, L., Howell, M. E. A., Hensley, C. R., Ning, K., Moorman, J. P., Yao, Z. Q., & Ning, S. (2023) · Journal of Virology · doi:10.1128/jvi.00953-23 · Cited by 5
Silymarin inhibits Toll-like receptor 8 gene expression and apoptosis in Ramos cancer cell line.
Ranjbar, N., Saravani, R., & Faezizadeh, Z. (2020) · PubMed Central · doi:10.22038/ajp.2019.13681 · Cited by 5
Winkler, B. S., Oltmer, F., Richter, J., Bischof, J., Xu, P., Burster, T., Leithäuser, F., & Knippschild, U. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00009 · Cited by 4
Klein, G. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46808-5_7 · Cited by 4
Kovalevska, L. M., Golenkov, O. G., Kulahina, Y., Callender, T., Sizov, F. F., & Kashuba, E. (2022) · Life · doi:10.3390/life12030376 · Cited by 4
Gammaherpesviruses: Epstein-Barr Virus
Epstein, M. A., & Crawford, D. (2010) · doi:10.1002/9780470688618.taw0235 · Cited by 4
Wechselwirkungen von Proteinen mit den zytoplasmatischen Domänen der Mannose-6-Phosphat-Rezeptoren
Storch, S. (2001) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-662 · Cited by 4
Human Papillomaviruses, Tumour Suppressor Genes and Cervical Cancer
Inman, G. J., Cook, I. D., & Lau, R. K. W. (1993) · International Journal of STD & AIDS · doi:10.1177/095646249300400302 · Cited by 4
Mukhopadhyay, T., Maxwell, S. A., & Roth, J. A. (1995) · Molecular biology intelligence unit · doi:10.1007/978-3-662-22275-1_3 · Cited by 4
p53 Codon 213 (A-G) Polymorphism in a Turkish Population
İlhan, İ. E., Erekul, S., Ateşalp, S., İlhan, O., & Akar, N. (1995) · Pediatric Hematology and Oncology · doi:10.3109/08880019509009482 · Cited by 3
Shah, A., & Seedhouse, C. (2012) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-012-0203-1 · Cited by 3
RetractedWei, T., Williams, R. T., & Lavin, M. F. (1997) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400231 · Cited by 3
Lama, R., Wu, W., Mavis, C. K., Ruiz, F. M., Querol-García, J., Martin, D., Chemler, S. R., Chandra, D., Goodrich, D. W., Hernandez‐Ilizaliturri, F. J., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1462231 · Cited by 3
Insights into Apoptosis Mechanisms Induced by DNA-Damaging Agents in Burkitt's Lymphoma Cells
Magluta, E. P. S., Vasconcelos, F. D. C., Maia, R. C., & Klumb, C. E. (2009) · Cancer Investigation · doi:10.1080/07357900902849624 · Cited by 2
Sample, J. T., & Ruf, I. K. (2006) · Infectious disease and therapy · doi:10.3109/9781420014280.010 · Cited by 2
Studies of the p53 gene mutation in Saudi non-Hodgkin's lymphoma
Ahmad, M. F., Nasrin, N., Akhtar, M., & Hannan, M. A. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04255-3 · Cited by 1
Kuze, T., Nakamura, N., Hashimoto, Y., Hojo, H., Abe, M., & Wakasa, H. (1996) · Pathology International · doi:10.1111/j.1440-1827.1996.tb03588.x · Cited by 2
MDM4 is an essential disease driver targeted by 1q gain in Burkitt lymphomaPreprint
Hüllein, J., Slabicki, M. M., Rosołowski, M., Jethwa, A., Habringer, S., Tomska, K., Kurilov, R., Lu, J., Scheinost, S., Wagener, R., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/289363 · Cited by 2
Middleton, G., & Lau, R. (1992) · International Journal of STD & AIDS · doi:10.1177/095646249200300304 · Cited by 2
Animal Models of Burkitt’s Lymphoma
Vrazo, A. C., Chauchard, M., Çen, O., & Longnecker, R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4313-1_15 · Cited by 1
Pappa, V. I., & Young, B. D. (2006) · Elsevier eBooks · doi:10.1016/b978-0-7216-0081-9.50007-8 · Cited by 1
Context-dependent regulation of immunoglobulin mutagenesis by p53
Böttcher, K., Braunschmidt, K., Hirth, G., Schärich, K., Klassert, T. E., Stock, M., Sorgatz, J., Fischer‐Burkart, S., Ullrich, S., Frankenberger, S., et al. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.08.005 · Cited by 1
Mechanism of superior B cell immortalisation activity of type 1 Epstein-Barr virus
Tzellos, S. (2014) · Spiral (Imperial College London) · doi:10.25560/23223 · Cited by 1
Sugden, B. (2014) · ASM Press eBooks · doi:10.1128/9781555818302.ch12 · Cited by 1
p53 Gene Polymorphisms in the Turkish Population.
Akar, N., Akar, E., & Cin, S. (1999) · PubMed · Cited by 1
A Transgenic Model to Study the Role of Oncogenes and Tumour Suppressor Genes in T-Cell Lymphoma
Blyth, K. (1996) · Enlighten: Theses (The University of Glasgow) · Cited by 1
Gene Expression in Burkitt’s Lymphoma Cells
Jacquemin, M. G., Sinclair, A. J., & Farrell, P. J. (1994) · Frontiers of virology · doi:10.1007/978-3-642-85004-2_17 · Cited by 1
Self-citationAlpha-Actinin-4 Supports B Cell Survival by Limiting Lateral BCR Mobility
Alsouri, S. (2023) · doi:10.53846/goediss-10139 · Cited by 1
Tumour Suppressor Genes in Hodgkin’s Disease
Piris, M. A., Martinez, J. C., Sánchez‐Beato, M., García, J. F., Bellas, C., Menárguez, J., Villuendas, R., & Lloret, E. (1995) · Springer eBooks · doi:10.1007/978-1-4613-0339-8_17
Molecular definition of Burkitt Lymphoma
Boerma, E.-J. G. (2009) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Targeting of the Myc pathway as a novel approach for cancer therapy
Mo, H. (2006) · Figshare
A Functional Analysis of the RNA Polymerase II Large Subunit C-Terminal Domain
Chapman, R. D. (2003) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.1104
Shah, A., & Seedhouse, C. (2014) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-014-0422-8
RetractedEpstein-Barr Virus Lymphomagenesis and Therapeutic Targets
Rao, H., & Miranda, R. N. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5851-7_4
Ershler, W. B., Dunn, B. K., & Longo, D. L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_49
Molecular Biology of Virally-Induced Cell Transformation and Tumorigenesis
Boone, L. R., Moore, K. G., Phelps, W. C., & Woo, Y. (1995) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-4076-1_30
State-of-the-Art Review Gene Therapy of Lymphoma
Buttgereit, P. (2002)
Gasparotto, D., Maestro, R., Vukosavljevic, T., Piccinin, S., Sandrin, A., Rizzo, S., & Boiocchi, M. (1995) · Tumori Journal · doi:10.1177/030089169508100411
Prokocimer, M., & Rotter, V. (2011)
Cartlidge, R. C. (2015) · University of Birmingham Institutional Research Archive (University of Birmingham)
Li, H., Luo, X., Hu, J., Liu, S., Li, N., Tang, M., Weng, X., Wei, Y., Gao, J., Bode, A. M., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/383497
ROLE OF ZEBRA PROTEIN OF EPSTEIN-BARR VIRUS
الأسود, إ. ع. (2011) · Iraqi Journal of Biotechnology
The role of NFκB in glucose import and survival of B-cell lymphomas
Sommermann, T. G. (2012) · OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg)
Panel of Selected Burkitt's Lymphoma Cell Lines
(2001) · Elsevier eBooks · doi:10.1016/b978-012221970-2/50440-x
Bornkamm, G. W., Kelly, G. L., & Ross, A. M. (2025) · Current topics in microbiology and immunology · doi:10.1007/82_2025_301 · Cited by 2
Control of the EBV growth transformation programme : the importance of the Bamhi W repeats
Kao, K.-Y. (2011) · University of Birmingham Institutional Research Archive (University of Birmingham)
Les lymphomes B diffus à grandes cellules de type activé : rôle de NF-κB et c-Myc.
Arnaud, N. (2017) · theses.fr (ABES) · doi:10.70675/f86c2a1cz9979z400dz8e23ze8914714a1a8
Factors That Affect Chromosomal Translocations in Cells
Canoy, R. J. (2021) · theses.fr (ABES) · doi:10.70675/9f331f7az9151z4c95zbf47zbc6ed65a5896
Investigating the anti-apoptotic role of EBV in endemic Burkitt lymphona
Fitzsimmons, L. (2015) · University of Birmingham Institutional Research Archive (University of Birmingham)
Molecular Genetics of Rare Lymphomas
Wenzel, S.-S., & Lenz, G. (2014) · Springer eBooks · doi:10.1007/978-3-642-39590-1_3
Wilson (1999) · doi:10.1002/1529-0131(199907)42:7
Metadata
- Authors
- Farrell, P. J., Allan, G. J., Shanahan, F., Vousden, K. H., & Crook, T.
- Affiliations
- St Mary's Hospital (GB)
- Venue
- The EMBO Journal
- Published
- 1991-10-01
- Volume
- 10
- Issue
- 10
- Pages
- 2879-2887
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- PMC
- PMC452998
- OpenAlex
- W196344020
- Cited by
- 254
- References
- 59
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 6 · 2018: 6 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 12 · 2013: 1 · 2012: 14
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The EMBO Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- p53, Burkitt lymphoma, TP53 mutation, B-cell lymphoma cell lines, loss of heterozygosity, tumor suppressor
- MeSH terms
- Alleles, Amino Acid Sequence, Animals, Base Sequence, Burkitt Lymphoma, DNA, DNA, Neoplasm, Humans, Molecular Sequence Data, Mutation, Precipitin Tests, RNA, Neoplasm, Tumor Cells, Cultured, Blotting, Southern, Blotting, Northern, Blotting, Western, Polymerase Chain Reaction, Tumor Suppressor Protein p53
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
